Hu J, et al. - In this investigation with 191 patients, including 104 hepatitis B e-antigen (HBeAg)(+) and 87 HBeAg(−) treatment-naive chronic hepatitis B (CHB), researchers assessed routinely available clinical noninvasive liver fibrosis markers and analyzed the markers in HBeAg(+) and HBeAg(−) CHB patients separately. In the time between January 1, 2016 and April 31, 2017, patients with CHB who were treatment naive and who had a liver biopsy at the hospital were recruited. Serum alkaline phosphatase (ALP) levels increased gradually in all patients and separately in HBeAg(−) CHB patients, but not in HBeAg(+) CHB patients. In treatment-naive HBeAg(−) CHB patients, findings suggested that serum ALP levels can recognize significant fibrosis (S≥2) and may lessen the need for liver biopsies and help guide CHB's clinical therapy.